VIRX News and Press, Viracta Therapeutics Inc. From 12/16/21

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index PR Newswire SAN DIEGO , Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it h...

Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021 <span class="legendSpanClass">Vecabrutinib enhanced the efficacy of CAR T-cells in a murine mantle cell lymphoma model</span> <span class="legendSpanClass"...

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021 Complete responses (CR) observed across multiple Epstein-Barr virus-...

The FDA grants orphan drug designation (ODD) to Viracta Therapeutics' (NASDAQ:VIRX) all-oral combination product candidate, nanatinostat and valganciclovir (Nana-val), for the treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS). Sh...

Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals NRXP +48% after Zyesami increased likel...

Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma Fourth U.S. FDA orphan drug designation granted for Nan...

Viracta Therapeutics (NASDAQ:VIRX): Q3 GAAP EPS of -$0.40 misses by $0.09. Cash and cash equivalents totaled approximately $111.0 million as of September 30, 2021. Viracta expects to end 2021 with greater than $100.0 million in cash and cash equivalents, which it anticipates will be sufficien...

Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced that final results of Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma were selected f...

Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance PR Newswire SAN DIEGO , Nov. 5, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targetin...

Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting Final results from the Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphom...